Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Up 6.3% – Here’s What Happened

Shares of Qualigen Therapeutics, Inc. (NASDAQ:QLGN) were up 6.3% during trading on Monday . The stock traded as high as $5.65 and last traded at $5.38. Approximately 544,634 shares traded hands during trading, a decline of 88% from the average daily volume of 4,423,192 shares. The stock had previously closed at $5.06.

Qualigen Therapeutics Stock Up 6.3%

The stock has a 50 day moving average of $2.41 and a 200 day moving average of $3.13.

Qualigen Therapeutics (NASDAQ:QLGN) last released its earnings results on Thursday, August 14th. The company reported ($1.00) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Qualigen Therapeutics stock. FNY Investment Advisers LLC bought a new position in Qualigen Therapeutics, Inc. (NASDAQ:QLGN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,548 shares of the company’s stock, valued at approximately $27,000. FNY Investment Advisers LLC owned about 1.03% of Qualigen Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.18% of the company’s stock.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.